SCHEDULE: Beretta Bids for More Sturm Ruger Shares at 20% Premium

Beretta Holding S.A. proposes a tender offer for an additional 20.05% of Sturm Ruger & Co Inc shares at $44.80 each, contingent on a poison pill exemption.

Summary

• Beretta Holding S.A. (the "Reporting Person") has filed Amendment No. 4 to its Schedule 13D regarding its investment in Sturm Ruger & Co Inc (the "Issuer").
• Beretta proposes to commence a tender offer for up to 20.05% of Sturm Ruger's outstanding shares of common stock not already owned by Beretta.
• The proposed purchase price is $44.80 per share, representing a significant premium of approximately 20% to the volume-weighted average price of Sturm Ruger's shares over the 60 trading days ending on March 24, 2026.
• The tender offer is contingent on Sturm Ruger's Board of Directors granting Beretta an exemption under the shareholder rights plan (poison pill) adopted by the Board on October 14, 2025.
• Beretta currently beneficially owns 1,587,000 shares, representing 9.95% of Sturm Ruger's common stock.
• Beretta states its primary objective is to act as a constructive strategic partner and is not seeking control of Ruger, despite the Board's accusations.
• Beretta expresses deep disappointment with the Board's conduct, accusing them of misrepresenting intentions and adopting defensive measures to protect a "value-destructive status quo."
• Beretta expects the Board to grant the exemption by no later than the close of business on March 31, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development for Sturm Ruger shareholders due to the premium tender offer, but the ongoing conflict with the Board introduces significant uncertainty regarding the offer's execution.

Positives

• The proposed tender offer provides an opportunity for Sturm Ruger shareholders to sell a portion of their shares at a significant premium of approximately 20% over the recent 60-day average price.
• Beretta Holding aims to be a constructive strategic partner, potentially enhancing Sturm Ruger's strategic positioning and long-term growth through its global distribution capabilities, operational expertise, and deep understanding of the firearms market.
• Beretta clarifies that it does not consider itself a direct competitor to Sturm Ruger within the U.S. market, focusing on different product segments and positioning.

Negatives

• Sturm Ruger's Board of Directors has suspended negotiations with Beretta Holding, leading to an impasse in discussions.
• Beretta expresses deep disappointment with the Board's and management's conduct, accusing them of being "disingenuous" and misrepresenting Beretta's intentions.
• The Board's existing shareholder rights plan (poison pill), adopted on October 14, 2025, unduly obstructs Beretta's ability to consummate the proposed tender offer.
• Beretta alleges that the Board's strategy is to portray Beretta as a threat to justify defensive measures and entrench incumbent directors, protecting a "value-destructive status quo."
• The tender offer is conditional on the Board granting an exemption to the poison pill, meaning the offer may not proceed if the Board refuses.

Risks

• The proposed tender offer is contingent on Sturm Ruger's Board granting an exemption to its shareholder rights plan (poison pill); if the exemption is not granted, the offer will not proceed.
• Ongoing conflict and lack of constructive engagement between a significant shareholder (Beretta) and the Board could create uncertainty and potentially hinder strategic initiatives.
• The Board's defensive measures and alleged entrenchment of incumbent directors could be perceived as prioritizing self-preservation over shareholder interests, potentially impacting long-term value.

Future Outlook

Beretta Holding S.A. expects Sturm Ruger's Board to promptly act in accordance with its fiduciary duties and grant the requested exemption to the poison pill by no later than the close of business on March 31, 2026. Beretta is prepared to meet with the Board and its financial advisor to finalize the details of the tender offer.

Management Comments

• "Beretta Holding's primary objective has been simple: to act as a constructive strategic partner and help reverse the decline in Ruger's operational and share price performance."
• "We are not seeking control of Ruger. Our strong desire and hope was, and remains, to enter into a strategic collaboration with the Company."
• "We are deeply disappointed by the disingenuous manner in which the Board and management have conducted themselves throughout the course of our engagement."
• "It is not Beretta Holding that poses a threat to Ruger shareholders – it is the Board's own refusal to engage constructively with a willing, proven and highly credible strategic partner."
• "Our patience has run out."
• "Beretta Holding will not proceed with the tender offer unless and until the Board grants this exemption and not doing so would make it clear that you are putting your own interests and self-preservation ahead of the best interests of your shareholders."
• "Our singular goal right now is to become a more significant shareholder and strategic partner with the proper incentive to help unlock additional value for the benefit of all shareholders."

Industry Context

StockSavvy.ai notes that this development highlights increasing shareholder activism within the firearms industry, where strategic investors like Beretta Holding S.A. are seeking to influence corporate direction and unlock value. The use of a 'poison pill' by Sturm Ruger's Board is a common defensive tactic against perceived hostile takeovers or creeping control, reflecting broader corporate governance battles seen across various sectors when a significant shareholder challenges incumbent management.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential to realize a significant premium on a portion of their shares through the tender offer; risk of the offer not proceeding if the Board denies the poison pill exemption; potential for enhanced long-term value if Beretta becomes a strategic partner.
• Board and Management: Under pressure to respond to a significant shareholder's premium offer; facing scrutiny regarding their fiduciary duties and defensive tactics; potential for changes in board composition or strategic direction.
• Company (Sturm Ruger): Opportunity for a strategic partnership that could leverage Beretta's global capabilities; risk of continued internal conflict and uncertainty if the dispute with Beretta escalates.

Next Steps

• Sturm Ruger's Board of Directors is expected to consider Beretta Holding S.A.'s request for an exemption to the shareholder rights plan (poison pill).
• The Board is expected to provide its approval for the exemption by no later than the close of business on March 31, 2026.
• If the exemption is granted, Beretta Holding S.A. is prepared to commence the tender offer for up to 20.05% of Sturm Ruger's outstanding shares.
• Beretta Holding S.A. is prepared to meet with the Board and its financial advisor in New York to finalize the details of the offer.

Key Dates

Recommendation

The proposed tender offer at a 20% premium presents a clear upside for existing shareholders, suggesting a 'hold' to await the Board's decision on the poison pill exemption. However, the offer's contingency and the ongoing conflict with management introduce significant execution risk, preventing a 'buy' recommendation until clarity emerges.

Keywords

Sturm Ruger, Beretta Holding, Tender Offer, Poison Pill, Shareholder Rights Plan, Firearms Industry, Corporate Governance, Strategic Investment, Shareholder Activism, Premium Offer